Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOGES SISAY

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1649264896
CMS profile
347171
Location
EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$634.09

41 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $634.09 41

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $182.46 12
Novartis Pharmaceuticals Corporation $163.59 6
Amgen Inc. $140.44 15
Mallinckrodt Hospital Products Inc. $57.77 2
E.R. Squibb & Sons, L.L.C. $44.07 3
PFIZER INC. $19.50 1
Sobi, Inc $13.70 1
ADMA BioManufacturing LLC $12.56 1

Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOGES SISAY

NPI 1649264896 · CMS profile ID 347171

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649264896?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOGES SISAY, NPI 1649264896, CMS profile ID 347171. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649264896?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MOGES SISAY, NPI 1649264896, CMS profile ID 347171. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649264896?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MOGES SISAY, NPI 1649264896, CMS profile ID 347171, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1649264896?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

41 matching records · $634.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 41 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–41 of 41.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $17.8912/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384127 CMS
Novartis Pharmaceuticals Corporation $8.2911/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384125 CMS
ABBVIE INC. $19.3911/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617985 CMS
Amgen Inc. $8.0611/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469805 CMS
Mallinckrodt Hospital Products Inc. $37.2410/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937526277 CMS
ABBVIE INC. $17.7609/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617983 CMS
ABBVIE INC. $9.4309/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617981 CMS
PFIZER INC. $19.5009/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949322871 CMS
Amgen Inc. $11.2709/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469803 CMS
ABBVIE INC. $27.3908/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617979 CMS
Sobi, Inc $13.7008/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940366985 CMS
Amgen Inc. $11.0908/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469801 CMS
Novartis Pharmaceuticals Corporation $40.2208/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384111 CMS
Mallinckrodt Hospital Products Inc. $20.5308/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937526275 CMS
Amgen Inc. $10.3808/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469799 CMS
Amgen Inc. $10.7307/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469797 CMS
Amgen Inc. $8.9907/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469795 CMS
ABBVIE INC. $17.5707/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617977 CMS
Amgen Inc. $10.1907/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469793 CMS
Amgen Inc. $10.9806/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469791 CMS
Amgen Inc. $9.2006/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469787 CMS
ABBVIE INC. $14.5706/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617975 CMS
Amgen Inc. $10.2806/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469785 CMS
Amgen Inc. $11.6606/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469789 CMS
ABBVIE INC. $18.0605/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617973 CMS
ABBVIE INC. $22.6005/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617971 CMS
ABBVIE INC. $7.1805/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617969 CMS
ABBVIE INC. $6.4704/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617967 CMS
ADMA BioManufacturing LLC $12.5604/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933558965 CMS
Amgen Inc. $8.4004/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469783 CMS
ABBVIE INC. $4.8303/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617965 CMS
E.R. Squibb & Sons, L.L.C. $12.8203/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932530141 CMS
Amgen Inc. $5.1003/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469781 CMS
Novartis Pharmaceuticals Corporation $62.0203/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384107 CMS
Amgen Inc. $5.8602/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469779 CMS
Novartis Pharmaceuticals Corporation $17.4602/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384119 CMS
E.R. Squibb & Sons, L.L.C. $16.3702/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932530139 CMS
ABBVIE INC. $17.2101/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617963 CMS
Amgen Inc. $8.2501/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469777 CMS
Novartis Pharmaceuticals Corporation $17.7101/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384115 CMS
E.R. Squibb & Sons, L.L.C. $14.8801/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932530127 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 17
PY2020 $314.72 33
PY2021 $919.34 66
PY2022 $634.09 41
PY2023 $61.34 4
PY2024 $241.07 21
PY2025 $115.35 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $172,640.25 7
PY2024 Recipient $104.58 1
PY2024 Principal investigator $382,387.43 9
PY2023 Principal investigator $336,411.57 23
PY2022 Recipient $119.00 1
PY2022 Principal investigator $317,946.58 63
PY2021 Principal investigator $333,885.98 38
PY2020 Recipient $169.00 1
PY2020 Principal investigator $109,610.11 16
PY2019 Principal investigator $188,780.60 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,930.01 12/31/2023 Non-covered Recipient Entity
Qualmedica Research, LLC
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1042522757
Principal investigator 1 AstraZeneca UK Limited $236,376.66 10/16/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 991129681
Principal investigator 1 GlaxoSmithKline, LLC. $1,376.10 10/02/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 1006240379
Principal investigator 1 Novartis Pharmaceuticals Corporation $120.00 10/01/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis No dispute reported 06/30/2026 1017203525
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,856.00 09/28/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis No dispute reported 06/30/2026 1017240735
Principal investigator 1 ABBVIE INC. $4,595.05 09/07/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State No dispute reported 06/30/2026 998398697
Principal investigator 1 Eli Lilly and Company $415.32 07/26/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038127813
Principal investigator 1 ABBVIE INC. $327.04 07/13/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State No dispute reported 06/30/2026 998391101
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 07/06/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 1006240555
Principal investigator 1 GlaxoSmithKline, LLC. $1,078.00 07/06/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 1006240561
Principal investigator 1 GlaxoSmithKline, LLC. $17,520.20 06/20/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 1006240385
Principal investigator 1 ABBVIE INC. $21,482.47 06/05/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (SLEek) No dispute reported 06/30/2026 998385291
Principal investigator 1 ABBVIE INC. $8,300.00 05/16/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998383759
Principal investigator 1 Eli Lilly and Company $14,200.00 04/11/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A RANDOMIZED ACTIVE-CONTROLLED PARALLEL-GROUP PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1038133705
Principal investigator 1 GlaxoSmithKline, LLC. $1,401.30 03/21/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 1006240373
Principal investigator 1 ABBVIE INC. $289.44 02/16/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State No dispute reported 06/30/2026 998370869
Principal investigator 1 Eli Lilly and Company $554.82 02/08/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A RANDOMIZED ACTIVE-CONTROLLED PARALLEL-GROUP PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1038133725
Principal investigator 1 GlaxoSmithKline, LLC. $1,688.50 01/25/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 1006240543
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 01/25/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 1006240549
Principal investigator 1 GlaxoSmithKline, LLC. $947.70 01/25/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 1006240567
Principal investigator 1 GlaxoSmithKline, LLC. $297.90 01/12/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 1006240573
Principal investigator 1 Eli Lilly and Company $6,143.00 01/03/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038121659
Principal investigator 1 Novartis Pharmaceuticals Corporation $512.06 01/01/2023 Non-covered Recipient Entity
QUALMEDICA RESEARCH
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis No dispute reported 06/30/2026 1017204937